产品
编 号：F752872
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2451856-97-4
产品详情
生物活性：
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
体内研究：
Mupadolimab (10 mg/kg；腹腔注射；每天一次，持续 15 天) 刺激 SARS-CoV-2 感染的 NSG-SGM3 小鼠的抗原特异性体液免疫。Animal Model:NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)
Dosage:10 mg/kg
Administration:Intraperitoneal injection, daily for 15 days
Result:Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.
体外研究：
Mupadolimab 可诱导与 B 细胞成熟和抗原呈递相关的标志物表达增加、向浆母细胞的形态转化以及 IgM 和 IgG分泌增加。
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
体内研究：
Mupadolimab (10 mg/kg；腹腔注射；每天一次，持续 15 天) 刺激 SARS-CoV-2 感染的 NSG-SGM3 小鼠的抗原特异性体液免疫。Animal Model:NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)
Dosage:10 mg/kg
Administration:Intraperitoneal injection, daily for 15 days
Result:Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.
体外研究：
Mupadolimab 可诱导与 B 细胞成熟和抗原呈递相关的标志物表达增加、向浆母细胞的形态转化以及 IgM 和 IgG分泌增加。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备